Real-World Evidence For Accelerated Approval: NASEM Is A Tough Crowd
Executive Summary
Biopharma companies continue to hold out hopes that Real-World Evidence can help expand use of the US FDA accelerated approval pathway by making confirmatory studies more viable. A recent National Academies of Science, Engineering and Medicine workshop suggests there is a long way to go in building a broader consensus behind the approach.
You may also be interested in...
Accelerated Approval: US FDA Should Explain Why An Ongoing Trial Is Not Required
Having a confirmatory trial underway at the time of approval should be the ‘default expectation’ and the agency should publicly explain when and why it grants exceptions to this rule, experts said at a National Academies meeting on accelerated approval.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.